micrometastatic

mi·cro·met·a·stat·ic

(mī'krō-met'ă-stat'ik),
Denoting or characterized by micrometastasis, as in micrometastatic disease.

mi·cro·met·a·stat·ic

(mī'krō-met'ă-stat'ik)
Denoting or characterized by micrometastasis, as in micrometastatic disease.
Mentioned in ?
References in periodicals archive ?
Clinically node negative patients harbour a risk of micrometastatic lymph node involvement of up to 25%.
Pharmaceuticals published positive results from an analysis that demonstrated Oncotype DX should be an integral part of the treatment planning process for patients with node-positive micrometastatic breast cancer.
adjuvant therapy after surgery to control micrometastatic disease, and
Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells.
Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis.
These activated specific CTLs recognize, neutralize and destroy through cell lysis HER2 expressing cancer cells, including occult cancer cells and micrometastatic foci.
Katz has developed a patented blood test to detect micrometastatic circulating tumor cells in patients with prostate cancer that has not yet spread.
Available evidence suggests a lower rate of postoperative complications in patients who underwent completion lymph node dissection for micrometastatic disease detected by SLNB, compared to those who underwent therapeutic lymph node dissection for clinically palpable disease.
Management of micrometastatic disease, frequently in comparison with ITC, is another component of breast carcinoma addressed by much research.
This means that adjuvant cancer therapy, designed to kill presumed micrometastatic disease, may be missing an important fraction of disseminated cancer cells, some of which may eventually wake up.
As the node is sectioned in 2-mm slices, it is likely that any discordant result is based on tissue less than 2 mm thick and therefore a positive result on molecular analysis with no histological evidence of metastases could be reasonably treated as micrometastatic disease.
27) Breast cancer is a systemic disease and micrometastatic disease in the form of disseminated tumor cells (DTC) may be present in the bone marrow of breast-cancer patients at the time of diagnosis and, if present, is associated with a poorer distant metastasis-free survival.